EarningsQ3 2026 Earnings Report
MX:AMBUN Q3 2026 EPS Results
Actual EPS$1.65
Consensus EPS$1.74
Beat/MissMissed by -$0.09
One Year Ago EPS$1.29
MX:AMBUN Q3 2026 Revenue Results
Actual Revenue$4.60B
Expected Revenue$4.63B
Beat/MissMissed by -$26.99M
YoY Revenue Growth+8.83%
Earnings Announcement Details
QuarterQ3 2026
Date08/25/2026
TimeDuring Market Hours
Conference CallTuesday, August 25, 2026
MX:AMBUN Upcoming Earnings
Ambu's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:AMBUN Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong top-line momentum driven by Endoscopy (Respiratory and Urology/ENT/GI) with meaningful product and platform progress, robust cash generation and improved gross margin. Offsetting these positives were modest ongoing weakness in Anesthesia & Patient Monitoring, FX headwinds, residual tariff uncertainty and one-off commercial and project costs that depressed adjusted EBIT in Q3. Management confirmed updated guidance (~10% organic growth) and expects Q4 margin improvement driven by higher growth, tariff reclaims and operating leverage, while retaining medium-term margin ambitions.Company Guidance
Strong Overall Organic Growth
Reported 10.3% organic revenue growth in Q3 with a 12-month rolling organic growth of 9%. Company updated full-year revenue guidance to around 10% organic growth, confirming earlier trajectory.
Endoscopy Outperformance
Endoscopy Solutions grew ~16% overall in the quarter and now represents 64% of company revenue. Management reiterates Endoscopy guidance of +15% organic growth for the year and maintains a 15%–20% CAGR target over the ZOOM AHEAD period.
Respiratory Segment Momentum
Respiratory delivered 17.1% organic growth in Q3 (rolling 12 months 11.5%), driven by the bronchoscope portfolio (aScope 4 and aScope 5) and synergy with the new SureSight videolaryngoscope.
Urology, ENT & GI Growth
Urology, ENT & GI grew 15% in the quarter with rolling 12-month growth of 16.9%, driven by cystoscopes and ENT products and supported by recent U.S. commercial adjustments positioning for sustained momentum.
Return to Positive Growth in A&PM
Anesthesia & Patient Monitoring returned to positive growth in Q3 at ~1.6% (rolling 12 months ~1.3%), with patient monitoring showing solid performance and new MRI/CT-compatible electrodes expected to support recovery.
Profitability — Reported EBIT and Gross Margin Improvement
Reported EBIT was 13.5% in Q3 (an improvement of 2.2 percentage points vs. the same quarter last year). Gross margin improved by ~60 basis points year-over-year to 59.5% (from 58.9%). Management expects reported EBIT to land in the upper end of the 12%–14% guidance range.
Strong Cash Generation
Net free cash flow of DKK 154 million in the quarter and quarterly cash conversion of 48%. Company reiterates full-year cash conversion guidance above 40%.
Product and Platform Innovation
Key launches/advances highlighted: SureSight videolaryngoscope, Neuroline Cup MRI/CT announcement, EndoIntelligence platform progress (including best-in-class cybersecurity validation for monitors), and continued momentum for aScope product family (aScope 4/5, Gastro, Uretero pipeline).
Commercial Execution Progress
Deliberate U.S. commercial adjustments (including splitting Urology and ENT sales forces and adding talent) are in place to deepen customer coverage and leverage the broader portfolio; management reports successful early execution and settling of the new structure.
MX:AMBUN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed